APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial [0.03%]
APUC-6基因在前列腺癌CHAARTED试验中的预后和预测生物标志物潜力研究
Xiaolei Shi,Amol C Shetty,Jarey Wang et al.
Xiaolei Shi et al.
Purpose: A six-gene panel involved in androgen production, uptake, and conversion (APUC-6: HSD3B1, HSD3B2, CYP3A43, CYP11A1, CYP11B1, CYP17A1) may define distinct clinical outcomes in metastatic prostate cancer. This stud...
Fam-Trastuzumab Deruxtecan in Recurrent Low-Grade Serous Ovarian Carcinoma With CLU/NRG1 Fusion and Low Human Epidermal Growth Factor Receptor 2 Expression: A Case Report [0.03%]
CLU/NRG1融合和低人表皮生长因子受体2表达的复发性低级别浆液性卵巢癌使用Fam-Trastuzumab Deruxtecan治疗的病例报告
Aimee Keegan,Er Yue,Fang Fan et al.
Aimee Keegan et al.
Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials [0.03%]
超越P值:系统解读肿瘤临床试验的框架
Ruyue Li,Xue Dong,Xiujing Yao et al.
Ruyue Li et al.
In oncology, interpreting clinical trials solely through statistical significance (P < .05) often conflates true biological futility with methodological false negatives. This binary oversimplification risks prematurely abandoning active the...
Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay [0.03%]
年龄与NCI-MATCH试验靶向基因面板检测复发/难治性癌症肿瘤基因组特征的相关性
Hari Sankaran,Yuri Kotliarov,Yingdong Zhao et al.
Hari Sankaran et al.
Purpose: Motivated by the rising incidence of cancers at younger ages, this study compares tumor genomic alterations between adolescents and young adults (AYAs; 18-39 years) and non-AYAs (40 years and older) and explores ...
DPYD-Guided Dosing of Metronomic Capecitabine Plus Vinorelbine in Metastatic Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Real-World Retrospective Study [0.03%]
基于DPYD指导的节律性卡培他滨联合长春瑞滨治疗HER2阴性的转移性乳腺癌的回顾性研究
Francesco Schettini,Alexandro Membrino,Giuseppe Di Grazia et al.
Francesco Schettini et al.
Purpose: Metronomic chemotherapy with oral capecitabine + vinorelbine (Cape + VNL) provides synergistic cytostatic activity and antiangiogenic and immunomodulatory effects, potentially offering prolonged disease control w...
Identification of Predictive Biomarkers for Chemoradiotherapy Response in Rectal Cancer [0.03%]
识别预测放化疗反应的直肠癌生物标志物
Mee-Na Park,Junho Kang,Jeong-Woo Hwang et al.
Mee-Na Park et al.
Purpose: Chemoradiotherapy (CRT) is a standard treatment for rectal cancer, yet patients show marked variability in response. Identifying reliable biomarkers that predict CRT response remains an unmet clinical need. ...
Using Disease-Agnostic Genomic Liquid Biopsy in Complex Diagnoses: Real-Life Example of cfChIP-Seq in a Fever of Unknown Origin [0.03%]
基于基因组的液态活检在复杂疾病诊断中的应用——以持续发热原因不明为例
Orly Agmon Gutin,Jenia Gutin,Dania Jaber et al.
Orly Agmon Gutin et al.
Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma [0.03%]
IDH突变在肝内胆管癌预后价值的评估
Rachel N Harvey,Rebecca Gelfer,Esther Drill et al.
Rachel N Harvey et al.
Purpose: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations are common in intrahepatic cholangiocarcinoma (ICC), but their prognostic value is unclear. Using a large data set, we assessed their impact in resected ...
Knowledge and Attitudes on Germline Pharmacogenomic Testing Among Clinical Oncologists [0.03%]
临床肿瘤医生关于生殖系药物基因组检测的知识和态度
Mattie Monroe,Hetanshi Naik,James M Ford et al.
Mattie Monroe et al.
Purpose: Despite increasing evidence supporting the validity and utility of pharmacogenomic (PGx)-guided prescribing, clinical PGx testing in oncology remains limited. However, expanding professional guidelines and recomm...
Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK [0.03%]
基于NTRK基因融合罕见肿瘤患者的现实世界证据:德国多中心患者队列研究REALTRK的最终结果
Karin Potthoff,Sebastian Lange,Thomas Seufferlein et al.
Karin Potthoff et al.
Purpose: TRK inhibitors (TRKis) have transformed the therapeutic landscape for patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive tumors. However, approval of TRKis is based on evidence derive...
Multicenter Study
JCO precision oncology. 2026 Aug;10(8):e2600283. DOI:10.1200/PO-26-00283 2026